Application Of Somatostatin In Early Postoperative Inflammatory Small Bowel Obstruction

Objective:EPISBO (early postoperative inflammatory small bowel obstruction) is one of the common postoperative complications which appear soon after the abdomen surgery. It is caused by the weakening or evanishment of the intestinal tract power because of the inflammatory edema in the intestinal wall. The principal clinical manifestation is the distension of the abdomen, the weakening or vanishing of the abdominal rumbling sound with no abdominal pain. For the lack of the understanding of this kind of disease in the past, we used to adopt the surgery to treat which can easily cause many kinds of serious complications, like postoperative intestinal fistula and short intestines syndrome. In recent years, most scholars hold that EPISBO can be cured through the conservative treatment. However, how to promote or speed up the fast recovery from EPISBO remains to be one of clinical research subjects. At present, it is widely disputed clinically that whether somatostatin used to treat EPISBO can accelerate or promote the recovery from EPISBO. This research aims to make it clear that somatostatin can accelerate or promote the EPISBO recovery through contrastive observation among a large number of clinical cases.Method:We divide, according to the principle of randomized control, the 70 cases of EPISBO in our department from January 2005 to December 2009 into the regular treatment group (the control group,33 cases) and the somatostatin plus regular treatment group (somatostatin group,37 cases), observe and contrast the clinical curative effects, the length of stay and the cost of the two groups, and observe dynamically the result of lab CPK (Creatine phosphoric acid activating enzyme).Results:1. The 70 patients in the two groups all adopt the conservative method to treat the case of non-intestinal colic by being transferred to the operation.2. The clinical curative effect of the somatostatin group is more obvious than that of the control group:the average time in hospital reduces obviously and the expense drops. And the result of the iconography inspection are gets improved.Conclusion:1. Somatostatin can suppress the fluid secretion in the digestive tract, alleviate the expansion and promote intestinal peristalsis. It plays an obvious role in dealing with EPISBO, like shortening its course, alleviating the pain of the patients, advancing its recovery and shortening the length of stay in hospital.